|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
CytRx Corporation
| | | Phone: | (310) 826-5648 | Fax: | (310) 826-6139 | Year Established: | 1985 | Ticker: | CYTR | Exchange: | NASDAQ | Main Contact: | David J. Haen, VP, Business Development | | Other Contacts: | Felix Kratz, VP, Drug Discovery Carrie Nodgaard, MBA, PMP, Director, Project Management Scott Wieland, Ph.D., Senior VP, Drug Development John Y. Caloz, CFO Benjamin S. Levin, General Counsel, VP, Legal Affairs & Corporate Secretary Daniel Levitt, M.D., Ph.D., CMO Steven A. Kriegsman, President & CEO
| | Company Description | CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx drug development pipeline includes programs in clinical development for numerous cancer indications. CytRx recently announced initiation of Phase 2 clinical trials to evaluate the safety and efficacy of its drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia and advanced prostate cancer, and a pharmacokinetic clinical trial in patients with brain cancer. CytRx plans to initiate a Phase 2 clinical trial with its oncology candidate INNO-206 as a treatment for soft tissue sarcomas following a dose escalation safety trial. CytRx's pipeline also includes tamibarotene, which the Company plans is testing in a Phase 2 clinical trial in patients with non-small-cell lung cancer, and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL). CytRx has recently completed its strategy of monetizing its non-core assets through the sale of its molecular chaperone technology to Denmark-based Orphazyme ApS in a transaction valued up to $120 million, the sale of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals, and the disposition of its remaining shares of RXi Pharmaceuticals in a series of transactions that provided CytRx with approximately $17 million in non-dilutive financing. | |
|
|
|
|
|